BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Increase in Short Interest

Posted by Defense World Staff on Mar 2nd, 2025

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 216,400 shares, an increase of 76.1% from the January 31st total of 122,900 shares. Based on an average trading volume of 219,300 shares, the short-interest ratio is presently 1.0 days. Approximately 5.9% of the shares of the company are sold short.

BioLineRx Trading Up 0.9 %

Shares of BioLineRx stock opened at $3.35 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The firm has a market cap of $11.15 million, a PE ratio of -0.38 and a beta of 1.41. The business’s fifty day moving average is $5.17 and its two-hundred day moving average is $14.40. BioLineRx has a fifty-two week low of $3.24 and a fifty-two week high of $57.20.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC bought a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BLRX. HC Wainwright dropped their target price on BioLineRx from $840.00 to $360.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. StockNews.com assumed coverage on BioLineRx in a research report on Tuesday, February 4th. They set a “hold” rating on the stock.

Get Our Latest Analysis on BLRX

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.